FLD-103 / Feldan Therap - LARVOL DELTA

Zydus invests in Feldan Therapeutics to drive innovation in intracellular drug delivery (BioSpectrum India) - "Zynext Ventures USA LLC, the venture capital arm of Ahmedabad-based Zydus Lifesciences, has announced its investment in Feldan Therapeutics, a Canada-based early clinical-stage pharmaceutical company pioneering the development of treatments based on intracellular delivery of therapeutics. Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities. The company's lead candidate, FLD-103, is administered directly into basal cell carcinoma (BCC) lesions, where the Shuttle peptide facilitates the delivery of a Hedgehog inhibitor to its target within BCC cells."

Financing • Basal Cell Carcinoma

A Phase 1/2a, First-In-Human, Single and Multiple Ascending Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Intralesional FLD-103 in Subjects with Basal Cell Carcinoma (BCC) (ANZCTR) - P1 | N=18 | Recruiting | Sponsor: Feldan Therapeutics | Not yet recruiting ➔ Recruiting | Initiation date: Oct 2024

Enrollment open • Trial initiation date • Basal Cell Carcinoma • Non-melanoma Skin Cancer • Oncology • Skin Nodular Basal Cell Carcinoma

Feldan Therapeutics Announces the treatment of the first patient in the Phase 1/2a clinical trial of its candidate FLD-103, against basal cell carcinoma (Canada Newswire) - "Feldan Therapeutics...has announced its first patient being dosed in Phase 1/2a clinical study of Lead development candidate FLD-103; an intralesional injection intended to provide an alternative to surgery to patients diagnosed with basal cell carcinoma (BCC)....The trial is planned to enrol approximately 70 adult patients affected by BCC who will receive treatment for a maximum of 28 days. It includes an open-label single and multiple ascending dose escalation followed by a placebo-controlled dose expansion."

Trial status • Basal Cell Carcinoma

A Phase 1/2a, First-In-Human, Single and Multiple Ascending Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Intralesional FLD-103 in Subjects with Basal Cell Carcinoma (BCC) (ANZCTR) - P1 | N=18 | Not yet recruiting | Sponsor: Feldan Therapeutics

New P1 trial • Basal Cell Carcinoma • Non-melanoma Skin Cancer • Oncology • Skin Nodular Basal Cell Carcinoma

FELDAN THERAPEUTICS SECURES $16.5M SERIES B TO BRING LEAD ASSET TO CLINICAL DEVELOPMENT (PRNewswire) - "Feldan Therapeutics...has announced the initial closing of a $16.5 million Series B investment. The funds will primarily be used to conduct clinical phases I/II for Feldan's FLD-103, an intralesional treatment against basal cell carcinoma (BCC), and to advance its pulmonary program to the preclinical stage."

Financing • Basal Cell Carcinoma • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor